ChemPartner has a comprehensive ADC (Antibody-Drug Conjugate) research and development platform and over a decade of experience. With a robust team specializing in linker-payload design synthesis, antibody discovery, and ADC conjugation as well as in vitro and in vivo validation, for a tailored, all-in-one service from target or toxin initiation to pre-clinical.
Our experienced chemistry team has designed and synthesized hundreds of linkers and payloads (including toxins and non-toxins), providing continuous support for the ADC research. We excel in the development of ADC compounds featuring hydrophilic groups, charged moieties, click chemistry, branched multi-drug linkers, and bio-orthogonal linkers. We also possess a catalog of linker-toxin products. With a wealth of experience in various conjugation and analytical methods, we can also swiftly develop customized ADC conjugation approaches.
Payloads
According to client requirements, we optimize cytotoxic or non-cytotoxic payloads.
Cytotoxic Payloads
- Auristatins (MMAE and MMAF)
- Tubulysin
- PBD Dimer
- Maytansinoids (DM-1, DM-4)
- Duocarmycin
- Camptothecin (Exatecan, DXd, Topotecan, SN38, etc.)
- Doxrubicin (DOX, PNU-159682 derivatives, etc.)
Non-cytotoxic Payloads
- TLR agonists
- Steroids
- STING agonists
- LXR agonists
- VDR agonists
- THR-beta agonists
Linker Technologies
Based on the drug release mechanism, we design and synthesize ADC linkers (cleavable and non-cleavable, self-immolation, and peptide). Additionally, we can provide various specialized linkers such as branched, highly hydrophilic, and more.
Cleavable Linkers
- Enzyme Cleavage
- Lysosome cleavage
- Cathepsin cleavage
- β-Glucuronidase cleavage
- Esterase cleavage
- Phosphatase cleavage
- Reducible disulfide linker
- pH Sensitive Linker
- Orthoester and acetal, ketal and dialkyl or diaryldialkoxysilane, carbonate, hydrazine
